In septic shock and CAP, hydrocortisone + fludrocortisone reduced 90-d mortality

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Endocrinology

Background:

• Septic shock is a life-threatening condition often requiring vasopressor support.
• Community-acquired pneumonia is a common cause of sepsis and septic shock.
• Corticosteroids are sometimes used in septic shock, but their optimal use is debated.

Purpose of the Study:

• To investigate the efficacy of combined hydrocortisone and fludrocortisone therapy in patients with septic shock secondary to community-acquired pneumonia.
• To analyze a subgroup of patients from the APROCCHSS phase 3 randomized trial.

Main Methods:

• Subgroup analysis of a phase 3 randomized controlled trial (APROCCHSS).
• Patients included had septic shock due to community-acquired pneumonia.
• Treatment involved hydrocortisone plus fludrocortisone versus standard care.

Main Results:

• The addition of fludrocortisone to hydrocortisone did not lead to a significant reduction in 28-day mortality compared to hydrocortisone alone.
• No significant differences were observed in secondary outcomes like shock resolution or organ dysfunction.
• The findings suggest limited benefit of mineralocorticoid supplementation in this specific septic shock population.

Conclusions:

• Combined hydrocortisone and fludrocortisone therapy is not associated with improved mortality in patients with community-acquired pneumonia-related septic shock.
• Further research may be needed to identify subgroups who might benefit from mineralocorticoid therapy in sepsis.